# Eleftherios P. Mamounas

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/eleftherios-p-mamounas/

## Facts

| Field | Value |
| --- | --- |
| Citations | 49,324 |
| Field | Breast Cancer Treatment Studies |
| h-index | 86 |
| i10-index | 200 |
| Last Known Institution | Orlando Health |
| OpenAlex ID | https://openalex.org/A5082509731 |
| ORCID iD | https://orcid.org/0000-0002-9476-2553 |
| Works | 393 |

## Researcher papers

- [Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-plus-adjuvant-chemotherapy-for-operable-her2-positive-breast-cancer/)
- [Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis](https://scholariq.org/papers/pathological-complete-response-and-long-term-clinical-benefit-in-breast-cancer/)
- [Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-emtansine-for-residual-invasive-her2-positive-breast-cancer/)
- [Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial](https://scholariq.org/papers/sentinel-lymph-node-resection-compared-with-conventional-axillary-lymph-node/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial](https://scholariq.org/papers/technical-outcomes-of-sentinel-lymph-node-resection-and-conventional-axillary/)
- [Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial](https://scholariq.org/papers/long-term-primary-results-of-accelerated-partial-breast-irradiation-after-breast/)
- [Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials](https://scholariq.org/papers/trastuzumab-for-early-stage-her2-positive-breast-cancer-a-meta-analysis-of-13/)
- [Statement of the Science Concerning Locoregional Treatments After Preoperative Chemotherapy for Breast Cancer: A National Cancer Institute Conference](https://scholariq.org/papers/statement-of-the-science-concerning-locoregional-treatments-after-preoperative/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Researcher university

- [Orlando Health](https://scholariq.org/institutions/orlando-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.